AspenBio Pharma Inc, has received a cash grant of approximately $250,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The $1 billion in funding and credits allocated to the QTDP Program is being distributed to companies with fewer than 250 employees whose research shows the greatest potential to result in new therapies that address areas of unmet medical need.
"The QTDP Program was designed to identify and support innovation. We are pleased that they recognize the potential of our AppyScore™ product—a novel, blood-based diagnostic test in development, designed to aid emergency department physicians in the difficult challenge of evaluating patients suspected of having appendicitis," said Steve Lundy, AspenBio’s chief executive officer and president. "This cash grant will help support our continued development activities."
Source: AspenBio Pharma Inc
